356 related articles for article (PubMed ID: 15818647)
1. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
4. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
5. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
6. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
Chan FK; Abraham NS; Scheiman JM; Laine L;
Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
Chen JT; Pucino F; Resman-Targoff BH
J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
10. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
[TBL] [Abstract][Full Text] [Related]
11. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L
Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
[TBL] [Abstract][Full Text] [Related]
14. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
Lanas A; Hunt R
Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
Inotai A; Mészáros A
Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
[TBL] [Abstract][Full Text] [Related]
16. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
17. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
[TBL] [Abstract][Full Text] [Related]
18. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A; Ferrandez A
Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
[TBL] [Abstract][Full Text] [Related]
19. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
20. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]